#Italy #Milan #NTC #Pharmathen #Wise Equity

NTC Strengthens Its Position in Ophthalmology Market

NTC S.r.l., a prominent player in the Italian pharmaceutical sector, has recently marked a significant milestone with the acquisition of Pharmathen's ophthalmology business. Supported by its main shareholder, Wise Equity, this move is set to enhance NTC’s portfolio, especially in the glaucoma segment, ultimately solidifying its competitive position within the European eye care market.

Expanding Portfolio and Market Presence

The acquisition provides NTC with around €100 million in revenue, over 80% of which comes from ophthalmology. This strategic transaction not only expands the company's product lineup but also strengthens its international presence, particularly in the U.S. market—a vital component for future growth. The newly integrated glaucoma product portfolio, which boasts a variety of recognized preservative-free formulations, aligns perfectly with NTC's focus on providing high-quality therapeutic solutions.

Insights from Leadership

Riccardo Carbucicchio, CEO of NTC, elaborates on the strategic significance of this acquisition, stating, "By integrating therapies to treat glaucoma, we bolster our commitment to delivering safe and reliable long-term treatments for patients in need." Stressing the importance of their network of global partners, Carbucicchio emphasizes their readiness to extend their offering internationally through well-established collaborations.

In a similar vein, John Nason, Group CEO of Pharmathen, noted that the partnership with NTC ensures that customers will experience continued investment in products that guarantee reliability and a broader-reaching supply chain. He believes that shifting this ophthalmic portfolio to NTC is a strategic move, enhancing the capability to support a wider array of patients.

A Market with Growing Demand

The global burden of glaucoma—expected to affect nearly 112 million individuals by 2040—highlights the pressing need for high-quality treatment options. NTC aims to address this need by enhancing its therapeutic coverage. The acquisition also leverages NTC's dedicated field force in Italy and Spain, where they already target ophthalmologists, enabling the introduction of glaucoma treatments within their existing therapeutic proposition.

The integration of Pharmathen's products is expected to yield considerable commercial synergies, opening up new avenues for growth internationally across more than 100 countries and over 250 distribution partners.

Continued Commitment to Innovation

With a robust pipeline catering to various ophthalmic conditions—including antibiotic therapies for eye infections and treatments for inflammation and allergies—over the past decade, NTC has established itself as a leader in the ophthalmology sector. The acquisition of Pharmathen's glaucoma portfolio joins this extensive pipeline, underscoring NTC’s intent to remain at the forefront of innovation in this specialized field.

The ability to offer a comprehensive glaucoma treatment range not only positions NTC advantageously in current markets but also enhances its capacity to respond to the increasing global demand for ophthalmic solutions. This strategic acquisition clearly sets the stage for NTC's continued growth and expansion within both the European and U.S. markets.

In summary, NTC's successful acquisition of Pharmathen's ophthalmology business heralds a new chapter for the company, reflecting its ambition to be a leading reference partner for firms looking to enter or expand in the ophthalmology landscape. As they move forward, the synergy between NTC and Pharmathen is expected to foster innovations that significantly improve patient care outcomes in the field of eye health.